Chai-2: The AI Model Accelerating Drug Discovery with Chai Discovery Co-Founders Jack Dent and Joshua Meier

In this episode of No Priors, Sarah interviews Josh Meyer and Jack Dent, co-founders of Chai Discovery, about their new AI-driven antibody discovery platform, Chai-2. Josh and Jack discuss the breakthroughs that led to the creation of Chai-2, including advancements in protein structure prediction and generative models. They explain how Chai-2 significantly improves the speed and success rate of antibody design compared to traditional methods, potentially unlocking new therapeutic targets. They also discuss the broader implications for the biotech industry, emphasizing the shift towards engineering biology with AI and opening access to Chai-2 for academic and industry partners. The conversation also covers the challenges and strategies in building a company at the intersection of AI and biology, emphasizing the importance of a strong engineering culture and interdisciplinary collaboration.